Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Trabectedin/PLD Versus Continuation of Platinum-based Chemo-therapy in Patients With Disease Stabilization and no Symptom Benefit Under Platinum-based Chemotherapy for Recurrent Ovarian Cancer

This is an open-label, prospective, randomized, controlled, parallel group, multi-center phase III trial to evaluate the Symptom Benefit Rate of trabectedin/PLD in patients with recurrent ovarian cancer who achieve a stabilization of disease after 3 cycles of platinum-based reinduction therapy and with no clinical benefit.

Study Overview

• Status: Terminated
• Conditions: Recurrent Ovarian Carcinoma
• Intervention / Treatment: Drug: Carboplatin; Drug: Gemcitabine; Drug: Bevacizumab; Drug: PLD; Drug: Paclitaxel; Drug: PLD; Drug: Cisplatin; Drug: Trabectedin

Detailed Description

Approximately 330 patients will be randomized in a 1:1 ration to the treatments specified below:

Arm A - Platinum-based chemotherapy according to investigator's discretion Arm B - Pegylated liposomal doxorubicin 30 mg/m² + Trabectedin 1.1 mg/m² (q3w)

• Study Type: Interventional
• Enrollment (Actual): 9
• Phase: Phase 3

Contacts and Locations

Study Locations

• Germany
  • Bad Homburg, Germany
    • Hochtaunus-Kliniken
  • Bamberg, Germany
    • Sozialstiftung Bamberg
  • Bergisch Gladbach, Germany
    • Evangelisches Krankenhaus Bergisch Gladbach
  • Berlin, Germany
    • Charité - Universitätsmedizin Berlin
  • Bonn, Germany
    • Universitätsfrauenklinik Bonn
  • Bottrop, Germany
    • Schwerpunktpraxis für Onkologie / Hämatologie
  • Braunschweig, Germany
    • Frauenärzte Casparistraße
  • Dresden, Germany
    • Universitätsklinikum Carl Gustav Carus
  • Essen, Germany
    • Evang. Kliniken Essen-Mitte
  • Frankfurt, Germany
    • Agaplesion Markus Krankenhaus
  • Greifswald, Germany
    • Universitätsmedizin Greifswald
  • Hamburg, Germany
    • Mammazentrum Hamburg am Krankenhaus Jerusalem
  • Itzehoe, Germany
    • Klinikum Itzehoe
  • Karlsruhe, Germany
    • Vidia Christliche Kliniken Karlsruhe
  • Ludwigsburg, Germany
    • Klinikum Ludwigsburg
  • Magdeburg, Germany
    • Klinikum Magdeburg
  • Mainz, Germany
    • Katholisches Klinikum Mainz
  • Mannheim, Germany
    • Universitätsfrauenklinik Mannheim
  • Memmingen, Germany
    • Klinikum Memmingen
  • München, Germany
    • Klinikum Rechts der Isar
  • Neumarkt, Germany
    • Kliniken des Landkreises Neumarkt
  • Oldenburg, Germany
    • Universitätsklinik für Innere Medizin, Onkologie und Hämatologie
  • Potsdam, Germany
    • Klinikum Ernst von Bergmann
  • Rotenburg, Germany
    • Agaplesion Diakonieklinikum Rotenburg
  • Saalfeld, Germany
    • Thüringen Kliniken "Georgius Agricola"
  • Stralsund, Germany
    • g.Sund Gyn. Kompetenzzentrum
  • Torgau, Germany
    • Kreiskrankenhaus "Johann Kentmann"
  • Wiesbaden, Germany
    • Helios Dr. Horst Schmidt Kliniken
  • Bayern
    • Aschaffenburg, Bayern, Germany, 63739
      • Klinikum Aschaffenburg-Alzenau

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Females aged ≥ 18 years at time of signing informed consent form.
2. Histologically proven diagnosis of cancer of the ovary, the fallopian tube or primary peritoneal cancer.
3. Measurable or non-measurable disease (according RECIST v1.1) or CA-125 assessable disease (according GCIG criteria) or histologically proven diagnosis of relapse.
4. Platinum-treatment free interval (TFIp) > 6 months prior to cycle 1 day 1 of reinduction therapy.
5. Disease stabilization without remission or progression ac-cording to RECIST or GCIG criteria after three cycles of platinum-based chemotherapy for recurrent disease.
6. Symptomatic disease at time of baseline abdominal/GI symptom scale score >15 (EORTC QLQ-OV28)
7. Completion of EORTC QLQ-OV28 at Baseline within 7 days prior to treatment start.
8. Patients should have received previously a taxane derivative.
9. ECOG performance status ≤ 2.
10. Life expectancy of at least 12 weeks.

11. Adequate bone marrow, renal and hepatic function defined as:

    • Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L
    • Platelet count ≥ 100 x 10^9/L
    • Hemoglobin ≥ 9.0 g/dL
    • Serum creatinine ≤1.5 mg/dL (≤ 132.6 µmol/L) or creatinine clearance ≥ 60 mL/min
    • Creatine phosphokinase (CPK) ≤ 2.5 x ULN
    • Serum aspartate aminotransferase (AST, SGOT) or alanine aminotransferase (ALT, SGPT) ≤ 2.5 x ULN (≤ 5 x ULN in the presence of liver metastases)
    • Alkaline phosphatase (ALP) ≤ 2.5 ULN
    • Serum bilirubin ≤ ULN
    • Albumin ≥ 25 g/l
12. Participation in an informed consent discussion with the appropriate trial-related health care representative, full understanding of the implications and constraints of the protocol, and provision of written informed consent prior to the commencement of the trial-related procedures.
13. Geographically accessibility for treatment and follow-up.
14. For women of childbearing potential (WOCBP): agreement to remain abstinent (refrain from heterosexual inter-course) or use a contraceptive method with a failure rate of < 1 per-centage per year during the treatment period and for at least six months after administration of the last dose of chemo-therapy. A woman is considered to be of childbearing po-tential if she is postmenarcheal, has not reached a post-menopausal state (≥ 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries, fal-lopian tubes, and/or uterus). Examples of contraceptive methods with a failure rate of < 1 percentage per year in-clude but are not limited to bilateral tubal ligation and/or oc-clusion, male sterilization, and intrauterine devices, and nor-mal and low dose combined oral pill plus male condom or Cerazette (desogestrel) plus male condom. Cerazette is currently the only highly efficacious progesterone based pill. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation meth-ods) and withdrawal are not acceptable methods of contra-ception.

Exclusion Criteria:

1. Ovarian tumors of low malignant potential (e.g. borderline tumors).
2. Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed Müllerian tumors).
3. Patients with an objective response in terms of a partial or complete remission or alternatively progressive disease ac-cording to RECIST or GCIG criteria after three cycles of platinum-based reinduction chemotherapy.
4. Patients who have received previous radiotherapy for ovarian cancer.
5. History of congestive heart failure (NYHA classification > 2, even if medically con-trolled).
6. History of myocardial infarction within the last six months (documented or by electrocardiogram).
7. History of atrial or ventricular arrhythmias.
8. Impaired liver function, hyperbilirubinemia, Serum creatinine >1.5 mg/dL or > 132.6 μmol/L or creatinine clearance < 60 mL/min, left ventricular ejection fraction < 45 %.
9. Severe active or uncontrolled infection.
10. Concurrent severe medical problems unrelated to malignancy, which would significantly limit full compliance with the trial or expose the patient to extreme risk or decreased life expectancy.
11. Patients with known hypersensitivity to the active substance or their compounds related to trabectedin or PLD and patients with known hypersensitivity to one of active substances or one of their compounds used in platinum-based chemotherapy as described in the Summaries of Medicinal Products.
12. Patients with potential risks according to contraindication, warnings or interactions of the used chemotherapeutic agents as stated in the SmPCs are not eligible for participation in this trial.
13. Patients with contraindication regarding CT or MRI (only in case of contrast allergy) are excluded.
14. Women of childbearing potential (WOCBP) not using highly effective contraceptive methods.
15. Pregnancy or breast-feeding.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: platinum-based chemotherapy; According to the investigator's discretion	Drug: Carboplatin; Administration according to investigator's discretion; Drug: Gemcitabine; Administration according to investigator's discretion; Drug: Bevacizumab; Administration according to investigator's discretion; Drug: PLD; Administration according to investigator's discretion; Drug: Paclitaxel; Administration according to investigator's discretion; Drug: PLD; Administration 30 mg/m² q21; Drug: Cisplatin; Administration according to investigator's discretion
Active Comparator: PLD + Trabectedin; PLD 30 mg/m² + Trabectedin 1.1 mg/m² q21	Drug: PLD; Administration according to investigator's discretion; Drug: PLD; Administration 30 mg/m² q21; Drug: Trabectedin; Administration 1.1 mg/m² q21

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Symptom Benefit Rate	Proportion of patients achieving a symptom benefit defined as an at least 10-point improvement according to EORTC QLQ-OV28; EORTC QLQ-OV28 is a questionnaire regarding Quality of Life specialized for Ovarian Cancer with points from 1 till 4 for each of the 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.	from Baseline to 8 or 9 weeks after randomization, assessed at each visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time until definitive deterioration (TUDD )	TUDD is defined as time from baseline until the first decrease in EORTC QLQ-C30 score ≥ 10 points (or 20 points) as compared at baseline; EORTC QLQ-C30 is a questionnaire regarding Quality of Life specialized for Cancer with points for each of the 30 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.	from Baseline until 24 months after randomization, assessed up to 54 months at each visit
Progression-free survival (PFS)	Progressive disease is based on investigator assessment using RECIST v1.1	PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first), assessed up to 54 months
Progression-free survival (PFS) rate at 6 months	Progressive disease is based on investigator assessment using RECIST v1.1	PFS is defined as time from randomization to disease progression according to RECIST v1.1, to death from any cause or to start of a new treatment (whichever occurs first) after six months
Response Rate (RR)	RR is based on investigator assessment using RECIST v1.1	from randomization until patients achieving complete response (CR) or partial response (PR) as best overall response, assessed up to 54 months
Global Health Status	based on Quality of Life; EORTC QLQ-C30 and EORTC QLQ-OV 28 are questionnaires for Quality of Life with points for each of the 30 or 28 questions (1=not at all, 2=a little, 3=quite a bit, 4=very much). Points will be summarized.	from baseline to end of treatment, assessed up to 54 months at each visit
Overall Survival (OS)	regular patient contact during the trila regarding life status	OS is defined as the time from randomization to death from any cause, assessed up to 54 months

Collaborators and Investigators

• Sponsor: AGO Research GmbH
• Investigators: Study Chair: Felix Hilpert, MD, PhD, Mammazentrum am Krankenhaus Jerusalem, Hamburg

Study record dates

Study Major Dates

• Study Start (Actual): August 9, 2019
• Primary Completion (Actual): March 3, 2021
• Study Completion (Actual): March 3, 2021

Study Registration Dates

• First Submitted: September 26, 2018
• First Submitted That Met QC Criteria: September 27, 2018
• First Posted (Actual): October 1, 2018

Study Record Updates

• Last Update Posted (Actual): February 24, 2022
• Last Update Submitted That Met QC Criteria: February 8, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: Symptom Benefit
• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Recurrence; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Antiviral Agents; Enzyme Inhibitors; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Antineoplastic Agents, Alkylating; Alkylating Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Agents, Immunological; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Gemcitabine; Carboplatin; Paclitaxel; Cisplatin; Bevacizumab; Trabectedin
• Other Study ID Numbers: AGO-OVAR 2.32

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No